Key result
Acyclovir normalizes liver function in a pediatric case of prolonged relapsing EBV hepatitis.
Why the study?
Most cases of Epstein-Barr virus hepatitis are mild, but severe and persistent forms are uncommon and may manifest with autoimmune hepatitis or underlying inborn errors of immunity.
Case Report (n=1)
Severe and persistent forms of EBV hepatitis are uncommon and may require antiviral therapy and investigation for underlying immunodeficiency or autoimmunity.
Epstein-Barr virus (EBV) infection is a self-limited disease, generally asymptomatic in children, and most cases of EBV hepatitis are mild. We report a pediatric case of EBV hepatitis with prolonged course, use of antiviral therapy, and screening for immunodeficiency associated with autoimmunity. School-age female, 8 years old, non-consanguineous parents, with a clinical history of fever, abdominal pain, and jaundice for 9 days. Complete blood count showed lymphocytic atypia; serologic investigation showed reactive EBV IgG and IgM, and non-reactive hepatitis A, HIV, CMV, and parvovirus. She remained clinically stable and was discharged for outpatient follow-up. She was readmitted 30 days later due to relapse of symptoms, painful cervical lymphadenopathy, elevated liver transaminases, and hepatosplenomegaly. Liver biopsy was indicated ‒ acute hepatitis with mild fibrosis and intense mononuclear portal and lobular inflammation. Immunohistochemistry for antibodies (CD3, CD4, CD8, CD20, and CD34 positive; CD21 negative; TDT negative; and nonspecific EBV) was suggestive of EBV-related hepatic inflammation, and workup for autoimmune hepatitis showed p-ANCA and c-ANCA, anti-LKM-1, anti-mitochondrial, anti-smooth muscle, and ANA all non-reactive. Immunologic screening ‒ serum immunoglobulins: IgA 209 mg/dL (between the P75 and P97 percentiles), IgM 190 mg/dL (above the P97 percentile), IgG 1,460 mg/dL (between the P75 and P97 percentiles) ‒ immunophenotyping: total lymphocytes 1,842 cells/μL, CD4+ (40.5%; 746 cells/μL), CD8+ (28.7%; 529 cells/μL), CD19+ (9.9%; 196 cells/μL) ‒ and quantitative serum PCR for EBV negative. Acyclovir was started due to altered liver function and later outpatient normalization. Epstein–Barr virus (EBV) is a ubiquitous herpesvirus that establishes lifelong latency in B cells and is typically controlled by robust T-cell and NK-cell responses. Severe and persistent forms of EBV hepatitis are uncommon and may be a manifestation of autoimmune hepatitis or an underlying inborn error of immunity. EBV-associated autoimmunity is still not fully understood, but there is evidence supporting its role in inducing T and/or B lymphocytes to produce liver-specific autoantigens. The relationship between inborn errors of immunity and EBV infection and hepatitis is multifaceted and clinically significant. In such cases, diagnostic investigation with liver biopsy and EBV-specific diagnostic tests (serology, PCR, in situ hybridization) are vital to confirm the diagnosis and guide treatment.
No takes yet. Share an insight, caveat, or question.
Paula et al. (2026) conducted a case report in Epstein-Barr virus infection with hepatic involvement (n=1). Acyclovir was evaluated. An 8-year-old female with prolonged Epstein-Barr virus hepatitis and relapse of symptoms was successfully treated with acyclovir, leading to outpatient normalization of liver function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: